Robert van Deursen

Robert van Deursen

Auto-generated profile, based on publicly available information

Robert van Deursen

School of Healthcare Sciences, Cardiff University, Cardiff, UK

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2016 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Open access
SBS. A. Bus
S. A. Bus
RDR. W. van Deursen
R. W. van Deursen
DAD. G. Armstrong
D. G. Armstrong
JLJ. E. A. Lewis
J. E. A. Lewis
CCC. F. Caravaggi
C. F. Caravaggi
O(on behalf of the International Working Group on the Diabetic Foot (IWGDF)
on behalf of the International Working Group on the Diabetic Foot (IWGDF)
Background: Footwear and offloading techniques are commonly used in clinical practice for preventing and healing of foot ulcers in persons with diabetes. The goal of this systematic review is to assess the medical scientific literature on this topic to better inform clinical practice about effective treatment.Methods: We searched the medical scientific literature indexed in PubMed, EMBASE, CINAHL, and the Cochrane database for original research studies published since 1 May 2006 related to four groups of interventions: (1) casting; (2) footwear; (3) surgical offloading; and (4) other offloading interventions. Primary outcomes were ulcer prevention, ulcer healing, and pressure reduction. We reviewed both controlled and non‐controlled studies. Controlled studies were assessed for methodological quality, and extracted key data was presented in evidence and risk of bias tables. Uncontrolled studies were assessed and summarized on a narrative basis. Outcomes are presented and discussed in conjunction with data from our previous systematic review covering the literature from before 1 May 2006.Results: We included two systematic reviews and meta‐analyses, 32 randomized controlled trials, 15 other controlled studies, and another 127 non‐controlled studies. Several randomized controlled trials with low risk of bias show the efficacy of therapeutic footwear that demonstrates to relief plantar pressure and is worn by the patient, in the prevention of plantar foot ulcer recurrence. Two meta‐analyses show non‐removable offloading to be more effective than removable offloading for healing plantar neuropathic forefoot ulcers. Due to the limited number of controlled studies, clear evidence on the efficacy of surgical offloading and felted foam is not yet available. Interestingly, surgical offloading seems more effective in preventing than in healing ulcers. A number of controlled and uncontrolled studies show that plantar pressure can be reduced by several conservative and surgical approaches.Conclusions: Sufficient evidence of good quality supports the use of non‐removable offloading to heal plantar neuropathic forefoot ulcers and therapeutic footwear with demonstrated pressure relief that is worn by the patient to prevent plantar foot ulcer recurrence. The evidence base to support the use of other offloading interventions is still limited and of variable quality. The evidence for the use of interventions to prevent a first foot ulcer or heal ischemic, infected, non‐plantar, or proximal foot ulcers is practically non‐existent. High‐quality controlled studies are needed in these areas.

1 May 2008 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
SBSicco Anthony Bus
Sicco Anthony Bus
GVG. D. Valk
G. D. Valk
RDR. W. van Deursen
R. W. van Deursen
DAD. G. Armstrong
D. G. Armstrong
CCC. Caravaggi
C. Caravaggi
PCP. R. Cavanagh
P. R. Cavanagh

26 January 2016 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
SBSicco Anthony Bus
Sicco Anthony Bus
DAD. G. Armstrong
D. G. Armstrong
RDR. W. van Deursen
R. W. van Deursen
JLJ. E. A. Lewis
J. E. A. Lewis
CCC. F. Caravaggi
C. F. Caravaggi
O(on behalf of the International Working Group on the Diabetic Foot (IWGDF)
on behalf of the International Working Group on the Diabetic Foot (IWGDF)

15 July 2004 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
OPO.R. Pearson
O.R. Pearson
MBM.E. Busse
M.E. Busse
RDR.W.M. van Deursen
R.W.M. van Deursen
CWC.M. Wiles
C.M. Wiles
Difficulty in walking is a major feature of neurological disease, and loss of mobility is the activity of daily living on which patients place the most value.1 Consequently, how to measure and assess this is of importance to any member of the inter-disciplinary team. In clinical practice, the World Health Organization international classification of functioning (ICF)2 is often adopted as the underlying framework for the assessment of mobility, which is an individual's ability to move about effectively in their environment.2 The ICF also introduces the constructs of performance (what an individual does in his environment) and capacity (ability to execute a task or action). This has a clear impact on the current methodology for the assessment of mobility. Different pathologies and impairments culminate in abnormal or reduced walking. For instance, in multiple sclerosis (MS), impairments such as weakness and spasticity from pyramidal tract lesions, loss of proprioception and co-ordination from dorsal column and cerebellar lesions, vestibular and visual dysfunction, cognitive and mood disturbance and pain may all contribute (Figure 1). In primary muscle disease, mobility is determined by weakness but secondary factors such as weight gain, contractures, fatigue and breathlessness may have important impacts. The degree of impairment has a non-linear relationship with activity and participation. For example leg strength and walking speed are poorly correlated,3 while many personal and environmental factors may influence the impact of similar degrees of loss of walking on mobility. Figure 1. Framework of international classification of function (ICF) as illustrated by mobility in MS. Impaired walking can be a marker of both disability and disease progression, and is therefore an important outcome measure in the treatment and rehabilitation of diseases such as MS and Parkinson's disease (PD). In some cases, measurement of mobility may have a direct influence on access to treatment. … Address correspondence to Dr O.R. Pearson, Section of Neurology, University of Wales College of Medicine, Cardiff CF14 4XN. e-mail: pearsonor{at}cardiff.ac.uk

1 June 2004 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
MBM E Busse
M E Busse
OPO R Pearson
O R Pearson
RDR Van Deursen
R Van Deursen
CWC M Wiles
C M Wiles
Background: A direct quantitative measurement of locomotor activity in an individual’s own environment over an extended period may help in evaluating the impact of impairments in neurological disorders. Objective: To investigate the reliability and validity of activity monitoring in neurological patients and healthy subjects. Methods: Initial reliability studies were completed on 10 healthy subjects and 10 mobility restricted neurological patients. Validity was investigated using 7 days of ambulatory monitoring with the Step Watch™ step activity monitor, laboratory based measures of gait and the Rivermead Mobility Index (RMI) in 10 patients with multiple sclerosis, 10 with Parkinson’s disease, and 10 with a primary muscle disorder. Additionally, 30 healthy subjects participated in the study. Two clinical illustrations of ambulatory monitoring are provided. Results: The mean (range) right step count of 7 days of monitoring in both healthy and neurological patients proved a reliable measure of activity (intra-class correlations 0.89 and 0.86 respectively). The 7 day mean (range) right step count was 5951 (2886−9955) in healthy subjects, 3818 (1611−5391) in patients with Parkinson’s disease, 3003 (716−5302) in those with muscular disorders, and 2985 (689–5340) in those with multiple sclerosis. A moderate correlation was noted between 7 day mean step count and gait speed (r = 0.45, p = 0.01) in the grouped neurological patients but not the RMI (rs = 0.3, p = 0.11). Conclusion: Ambulatory monitoring provides a reliable and valid measure of activity levels. Neurological patients, living independently, demonstrate lower activity levels than healthy matched controls. Ambulatory monitoring as an outcome measure has potential for improving the evaluation of ambulation and providing insight into participation.

20 February 2013 in Clinical Rehabilitation
Verified
Journal Article
Closed access
HKHanan Khalil
Hanan Khalil
LQLori Quinn
Lori Quinn
RDRobert van Deursen
Robert van Deursen
HDHelen Dawes
Helen Dawes
RPRebecca Playle
Rebecca Playle
MBMonica Busse
Monica Busse
The aim of this study was to explore feasibility, safety and outcome of an exercise intervention in people with Huntington’s disease. A randomized controlled pilot trial. A home-based exercise programme. A total of 25 subjects with early to mid-stage Huntington’s disease. Subjects were randomly allocated to either an exercise intervention (n = 13) or a control group (n = 12). Subjects in the exercise intervention group were asked to perform exercises at home three times a week for eight weeks using an exercise DVD, specifically developed for this purpose. The control group received their usual care. Adherence in the intervention group was calculated from exercise diaries. Measures of gait, balance, function, level of physical activity and quality of life were evaluated. Analysis of covariance was used to compare follow-up scores across groups after adjustment for chance baseline differences. Effect sizes were calculated. Eleven participants from the intervention and ten from the control group completed the study. Mean adherence was 29.4 SD 1.8 for the 32 prescribed sessions. There were no related adverse events. Differences between groups were observed in gait speed, balance, function and level of physical activity, but not quality of life as measured by the SF36. Effect sizes were large (>0.8) for the majority of the outcomes. Short-term structured home exercise programmes are feasible, beneficial and safe for people with early to mid-stage of Huntington’s disease. Our findings support the implementation of a larger trial of longer-term home exercise.